Lipoprotein(a) as an athero-thrombotic risk factor: Epidemiological evidence and possible pathogenetic mechanisms;La lipoproteina(a) come fatore di rischio atero-trombotico: Evidenze epidemiologiche e possibili meccanismi patogenetici

Giornale Italiano di Cardiologia

Volumn 26, Issue 10, 1996, Pages 1203-1225

  Lenzi, Silvia ^a   Scanu, Angelo ^b   De Caterina, Raffaele ^a,c  

^a Istituto di Clinica Medica II   (Italy)

^b UNIVERSITY OF CHICAGO   (United States)

^c Istituto Di Fisiologia Clinica   (Italy)

Author keywords

Atherosclerosis; Lipoprotein (a); Risk factors; Thrombosis

Indexed keywords

LIPOPROTEIN A;

ARTERIOSCLEROSIS; BLOOD; FIBRINOLYSIS; HUMAN; LIPID PEROXIDATION; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; THROMBOSIS; VASCULAR ENDOTHELIUM;

ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; LIPID PEROXIDATION; LIPOPROTEIN(A); RISK FACTORS; THROMBOSIS;

EID: 0030253269     PISSN: 00465968     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (189)

1. Utermann G: The mysteries of lipoprotein (a). Science 1989; 246: 904-910.
2. Berg K: A new serum type system in man - The Lp sistem. Acta Pathol Microbiol Scand 1963; 59: 369-382.
3. Dahlén GH, Ericson C, Furberg C: Electrophoresis of lipoproteins on cellulose acetate membrane. Acta Med Scand 1972; 192: 5-9.
4. Dahlén GH, Ericson C, Furberg C, Lundkvist L, Svarsudd K: Angina of effort and an extra pre-beta lipoprotein fraction. Acta Med Scand 1972; 192: 11-15.
5. Dahlén GH, Ericson C, Furberg C: Myocardial infarction and a pre-beta lipoprotein fraction. Acta Med Scand 1972; 192: 25-29.
6. Dahlén GH, Ericson C, Furberg C, Lundkvist L, Svarsudd K: Familial occurrence of an extra pre-beta lipoprotein fraction. Acta Med Scand 1972; 192: 17-20.
7. Dahlén GH, Berg K, Ramberg UB, Tamm A: Lp(a) lipoprotein and pre-beta-1-lipoprotein in young adults. Acta Med Scand 1974; 196: 327-331.
8. Berg K, Dahlén GH, Frick MH: Lp(a) lipoprotein and pre-beta-1-lipoprotein in patients with coronary heart disease. Clin Genet 1974; 6: 230-234.
9. Dahlén G, Guyton JR, Arrar M, Farmer JA, Kautz JA, Gotto AMJ: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-765.
10. Fless GMF, Zum Mallen ME, Scanu AM: Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem 1986; 261: 8712-8718.
11. Grinsteed GF, Ellefson RD: Heterogeneity of lipoprotein LP(a) and apoprotein(a). Clin Chem 1988; 34: 61036-61040.
12. Utermann G, Manzel HJ, Kraft HG, Duba HC, Kemmler HG, Seltz C: Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentration in plasma. J Clin Invest 1987; 80: 458-465.
13. Eaton DA, Fless GM, Kohr W et al: Partial amino acid sequence of apoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987; 84: 3224-3228.
14. Dahlén GH: Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994; 108: 111-126.
15. Scanu AM, Edelstein C: Kringle-dependent structural and functional polymorphism of apolipoprotein(a). Biochim Biophys Acta 1995; 1256: 1-12.
16. Boomsa DI, Kaptein A, Kempen HJ, Gevers Leuven JA, Princen HM: Lipoprotein(a): relation to other risk factors and genetic heritability. Result from a Dutch parent-twin study. Atherosclerosis 1993; 99: 23-33.
17. Perombelon YFN, Soutar AK, Knight BL: Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles. J Clin Invest 1994; 93: 1481-1492.
18. Rader DJ, Cain W, Loren A, Zech L, Uscher D, Brewer HB: Variation in lipoprotein(a) concentration among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993; 91: 443-447.
19. Rader DJ, Cain W, Katsunori I et al: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994; 93: 2758-2763.
20. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G: Changes of genetic apolipoprotein phenotypes caused by liver transplantations. Implications for apolipoprotein synthesis. J Clin Invest 1989; 83: 137-142.
21. Fless GM, Pfaffinger DJ, Eisenhart JD, Scann AM: Solubility, immunochemical and lipoprotein binding properties of apoB100-apo(a), the protein moiety of lipoprotein(a). ] Lipid Res 1990; 31: 909-918.
22. Scann AM, Fless GM: Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709-1715.
23. Scanu AM, Lawn RM, Berg K: Lipoprotein(a) and atherosclerosis. Ann Int Med 1991; 115: 209-218.
24. Scanu AM: Lipoprotein(a): its inheritance and molecular basis of its atherothrombotic role. Mol Cell Biochem 1992; 113: 127-131.
25. Hixon JE, Britten ML, Manis GS, Rainwater DL: Apolipoprotein(a) glycoprotein isoforms result from size differences in apo(a) mRNA. J Biol Chem 1989; 264: 6013-6016.
26. Gavish D, Azrolan N, Breslow JL: Plasma Lp(a) concentration is inversely correlated with the ratio of kringle 4/kringle 5 encoding domains in the apo(a) gene. J Clin Invest 1989; 84: 2021-2027.
27. Koshinsky ML, Beisiegel U, Henne-Bruns D, Eaton DL, Lawn RM: Apolipoprotein(o) size heterogeneity is related to variable number of repeat sequences in its mRNA. Biochemistry 1990; 29: 640-644.
28. Reblin T, Rader DJ, Beisiegel U, Greten H, Brewer HBJ: Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma. Atherosclerosis 1992; 94: 223-232.
29. Sullivan DR, Lam CWK, Jessup W, Dean RT, Hensley WJ: Postprandial changes in apolipoprotein(a) concentration of triglyceride-rich lipoproteins can be reproduced by in vitro incubation: implications for underlying mechanism. Atherosclerosis 1993; 103: 139-147.
30. Selinger E, Dalongeville J, Davignon J: Apolipoprotein(a) is present in triglyceride-rich fraction in type IV hypertriglyceridemia. Clin Biochem 1993; 26: 59-64.
31. Albers JJ, Marcovina JSM, Lodge MS: The unique lipoprotein(a): properties and immunochemical measurement. Clin Chem 1990; 36: 2019-2026.
32. Marz W, Siekmeier R, Gross E, Gross W: Determination of lipoprotein(a): enzyme immunoassay and immunoradiometric assay compared. Clin Chim Acta 1993; 214: 59-67.
33. Marz W, Siekmeier R, Gross W, Kostner GM: Determination of lipoprotein(a): evaluation of three methods. Eur J Clin Chem Clin Biochem 1993; 31: 295-302.
34. Craig WY, Ledue TB: The effect of long term storage on serum Lp(a) levels. Atherosclerosis 1991; 89: 59-67.
35. Marcovina SM, Albers JJ, Jacobs DR Jr et al: Lipoprotein(a) concentration and apolipoprotein(a) phenotypes in Caucasian and African Americans, the CARDIA study. Arteriosclerosis Thromb 1993; 13: 1037-1045.
36. Bovet P, Rickenbach M, Wietlisbach V et al: Comparison of serum lipoprotein(a) distribution and its correlates among black and white populations. Int J Epidemiol 1994; 23: 20-27.
37. Bihari-Varga M, Kostner G, Czinner A: Lp(a) and risk of coronary heart disease. Eur J Epidemiol 1992; 8: 33-35.
38. Cooke T, Sheahan R, Foley D et al: Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994; 89: 1593-1598.
39. Hiroinky D: Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with LDL apheresis. LDL apheresis angioplasty restenosis trial (L-ART) Group. AmJ Cardiol 1994; 73: 1037-1040.
40. Marburger C, Hambrecht R, Niebauer J et al: Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol 1994; 73: 742-746.
41. Slunga L, Johnson O, Dahlén GH, Eriksson S: Lipoprotein(a) and acute phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 1992; 52: 95-101.
42. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M: Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145-150.
43. Noma A, Abe A, Maeda S, Seishima M, Makino K, Yano Y, Shimokawa K: Lp(a): an acute-phase reactant? Chem Phys Lipids 1994; 67-68: 411-417.
44. Bewu M, Durrington PR, Bulleid S, Mackness MI: The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infartion on serum lipoprotein(a), apolipoprotein A1 and B, lipids and C-reactive protein. Atherosclerosis 1993; 103: 67-71.
45. Bewu ADM, Durrington PN, Mackness MI, Hunt WH, Turkie WH, Creamer JE: Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J 1994; 71: 316-321.
46. Brown SA, Morrisett J, Boerwinkle E, Hutchinson R, Patsch W: The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk In Communities (ARIC) Study. Arterioscl Thromb 1993; 13: 1139-1158.
47. Schreiner PJ, Morriset JD, Sharrett AR et al: Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arterioscler Thromb 1993; 13: 826-833.
48. Valentine RJ, Grayburn PA, Vega GL, Grundy SM: Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994; 154: 801-806.
49. Tato F, Keller C, Schuster H, Spengel F, Wolfram G, Zollner N: Relation of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis 1993; 101: 69-77.
50. Cambillau M, Simon A, Amar J et al: Serum Lp(a) as a discriminant marker of early atheroslerotic plaque at three extracoronary sites in hypercholesterolemic men. The PCVMETRA Group. Arterioscler Thromb 1992; 12: 1346-1352.
51. Tyrrel J, Cooke T, Reilly M et al: Lipoprotein(a) and peripheral vascular disease. J Intern Med 1992; 232: 349-352.
52. Pedro-Botet J, Senti M, August T et al: Apolipoprotein(o) genetic polymorphism and serum lipoprotein(a) concentration in patients with peripheral vascular disease. Atherosclerosis 1993; 104: 87-94.
53. Molgaard J, Klausen C, Lassvik C, Faergeman O, Gerdes LU, Olsson AG: Significant association between low-molecular- weight apolipoprotein(a) isoform and intermittent claudication. Arterioscler Thromb 1992; 12: 895-901.
54. Dahlén GH: Incidence of Lp(a) lipoprotein among populations. In: Scanu AM (ed): Lipoprotein(a). Academic Press, San Diego 1990; 151-170.
55. Watts GF, Kearney EM, Traub NA, Slavin BM: Lipoprotein(a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia. J Clin Pathol 1993; 46: 267-270.
56. Schaefer ES, Lamon-Fava S, Jenner J et al: Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994; 271: 999-1003.
57. Bowden JF, Pritcheard JS, Hill JS, Frohlich JJ: Lp(a) concentration and apo(a) isoform size: relation to the presence of coronary artery disease in familiar hypercholesterolemia. Arterioscler Thromb 1994; 14: 1561-1568.
58. Knijf P, Kaptein A, Boomsma D, Princen HMG, Frants RR, Havekes LM: Apolipoprotein-E polymorphism affects plasma levels of lipoprotein(a). Atherosclerosis 1991; 90: 169-174.
59. Feussner G, Wagner A, Ziegler R: Relation of cardiovascular risk factors to atherosclerosis in type III hyperlipoproteinemia. Human Genet 1993; 92: 122-126.
60. Parlavecchia M, Pancaldi A, Taramelli R et al: Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men < 55 years of age. Am J Cardiol 1994; 74: 346-351.
61. Ritter MM, Loscar M, Richter WO, Scwandt P: Lipoprotein(a) in diabetes mellitus. Clin Chim Acta 1993; 214: 45-54.
62. Nakata H, Horita K, Eto M: Alteration of lipoprotein(a) concentration with glycemic control in non insulin dependent diabetic subjects without diabetic complications. Metabolism 1993; 42: 1323-1326.
63. O'Brien T, Nguyen TT, Harrison JM, Bailey KR, Dyck PJ, Kottke BA: Lipids and Lp(a) lipoprotein levels and coronary artery disease in subjects with non-insulin-dependent diabetes mellitus. Mayo Clin Proc 1994; 69: 430-435.
64. Csaszar A, Dieplinger H, Sandholzer C et al: Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia 1993; 36: 47-51.
65. Rain water DL, McGluer JW, Stern MP, Vanderberg JL, Haffner SM: Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes 1994; 43: 942-946.
66. Farrer M, Game FL, Albers CJ et al: Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease. BMJ 1993; 307: 832-836.
67. Farrer M, Game FL, Albers CJ et al: Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb 1994; 14: 1272-1283.
68. Morisaki N, Yokote K, Tashiro J et al: Lipoprotein(a) is a risk factor for diabetic retinopathy in the elderly. J Am Geriatr Soc 1994; 42: 965-967.
69. Sutherland WH, Lewis Barned NJ, Pratt MC, Tillman HC, Walker RJ: The response of plasma lipoprotein(a) concentration to acute hyperinsulinemia in patients with non insulin-dependent diabetes and in healthy subjects. Res Commun Chem Pathol Pharmacol 1994; 83: 77-86.
70. Bagdade JD, Porte DJ, Bierman EL: Hypertriglyceridemia, a metabolic consequence of chronic renal failure. N Engl J Med 1968; 279: 181-185.
71. Chan MK, Varghese Z, Moorehead JF: Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 1981; 19: 625-637.
72. Webb AT, Plant M, Reaveley DA et al: Lipid and lipoprotein (a) concentrations in renal transplant patients. Nephrol Dial Transplant 1992; 7: 636-641.
73. Thomas ME, Freestone A, Varghese Z, Persaud JW, Moorhead JF: Lipoprotein(a) in patients with proteinuria. Nephrol Dial Transplant 1992; 7: 597-601.
74. Frank WM, Sreepada Rao TK, Manis T et al: Relationship of plasma lipids to renal function and length of time on maintenance haemodialysis. Am J Clin Nutr 1978; 31: 1886-1892.
75. Haas LB, Sherrad DJ, Brunzell JD: Hypertriglyceridemia and premature cardiovascular disease in patients on maintenance hemodialysis. Clin Res 1979; 27: Abstract 416.
76. Kasiske BL, O'Donnel MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33: 667-672.
77. Kasiske BL, O'Donnel MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62: 367-374.
78. Moorhead JF, Chan MK, El-Nahas M, Varghese Z: Lipid nephrotoxicity in chronic glomerular and tubulo-interstitial disease. Lancet 1982; 2: 1309-1311.
79. French JW, Yamanaka BS, Ostwald R: Dietary induced glomerulosclerosis in the guinea pig. Arch Pathol 1967; 83: 204-220.
80. Wellmann KF, Volk BW: Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits: II. Long term studies. Lab Invest 1971; 24: 144-155.
81. Peric-Golia L, Peric-Golia M: Aortic and renal lesions in hypercholesterolemic adult male, virgin Sprague-Dawley rats. Atherosclerosis 1983; 46: 57-65.
82. Al-Shebeb Y, Frslich J, Magil AB: Glomerular disease in hypercholesterolemic guinea pigs: A pathogenetic study. Kidney Int 1988; 33: 498-507.
83. Avram MM: Similarities between glomerular sclerosis and atherosclerosis in human renal biopsy specimens: a role for lipoprotein glomerulopathy. Am J Med 1989; 87: 39N-41N.
84. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC: Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 1987: 721.
85. Heimann P, Josephson MA, Fellner SK, Thistlethwaite JJ, Stuart FP, Dasgupta A: Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients. Am J Nephrol 1991; 11: 470-474.
86. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J: Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. Aust NZ J Med 1992; 22: 243-248.
87. Kandoussi A, Cachera C, Pagniez D, Dracon M, Fruchart JC, Tacquet A: Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD. Kidney Int 1992; 42: 424-425.
88. Thillet J, Faucher C, Issad B, Allouache M, Chapman J, Jacobs C: Lipoprotein (a) in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993; 22: 226-232.
89. Goldwasser P, Michel MA, Collier J et al. Prealbumin and lipoprotein (a) in hemodialysis: relationships with patient and vascular access survival. Am J Kidney Dis 1993; 22: 215-225.
90. Buggy D, Breathnach A, Keogh B, Cooke T, Feely J: Lipoprotein(a) and treatment of chronic renal disease. J Intern Med 1993; 234: 453-455.
91. Webb AT, Reaveley DA, O'Donnel M, O'Connor B, Seed M, Brown EA: Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8: 609-613.
92. Anwar N, Bhatnagar D, Short CD et al: Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8: 71-74.
93. Okura Y, Saku K, Hirata K et al: Serum lipoprotein (a) levels in maintenance hemodialysis patients. Nephron 1993; 65: 46-50.
94. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475-482.
95. Oida K, Takai H, Maeda H et al: Apolipoprotien(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992; 38: 2244-2248.
96. Guillausseau PJ, Peynet J, Chanson P et al: Lipoprotein(a) in diabetic patients with and without chronic renal failure. Diabetes Care 1992; 15: 976-979.
97. Haffner SM, Gruber KK, Aldrete GJ, Morales PA, Stern MP, Tuttle KR: Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol 1992; 3: 1156-1162.
98. Dieplinger H, Lackner C, Kronenberg F et al: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993; 91: 397-401.
99. Cressman MD, Hoogwerf BJ, Schreiber MJ, Cosentino FA: Lipid abnormalities and end-stage renal disease: implications for atherosclerotic cardiovascular disease? Miner Electrolyte Metab 1993; 19: 180-185.
100. Barbagallo CM, Averna MR, Sparacino Vet al: Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron 1993; 64: 560-564.
101. Karadi I, Romics L, Palos G et al: Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989; 35: 2121-2123.
102. Takegoshi T, Kitoh C, Haba T et al: A study of the clinical significance of lipoprotein (a) in nephrotic syndrome. Jpn J Med 1991; 30: 21-25.
103. Black IW, Wilcken DE: Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 1992; 38: 353-357.
104. Kanno H, Saito E, Fujioka T, Yasugi T: Lipoprotein(a) levels in the nephrotic syndrome. Intern Med 1992; 31: 1004-1008.
105. Short CD, Durrington PN, Mallick NP, Bhatnagar D, Hunt LP, MBewu A: Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. Nephrol Dial Transplant 1992; 7: 109-113.
106. Jenkins AJ, Steele JS, Janus ED, Best JD: Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 1991; 40: 787-790.
107. Kapelrud H, Bangstad HJ, Dahl-Jorgensen K, Berg K, Hanssen KF: Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 675-678.
108. Lenzi S, Caprioli R, Rindi P et al: Omega-3 fatty acid supplementation and lipoprotein(a) concentrations in patients with chronic glomerular diseases. Nephron 1996; 72: 383-390.
109. Gall MA, Rossing P, Hommel E et al: Apolipoprotein(a) in insulin dependent diabetic patients with and without diabetic nephropaty. Scand J Clin Lab Invest 1992; 52: 513-521.
110. Borba EF, Santos RD, Bonfa E et al: Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994; 21: 220-223.
111. Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlén GH: Lipoprotein(a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Reum Dis 1991; 50: 366-370.
112. Seckin D, Tokgozoglu L, Accaya S: Are lipoprotein profile and lipoprotein(a) levels altered in men with psoriasis? J Am Acad Dermatol 1994; 31: 445-449.
113. Barbir M, Kushwaha S, Hunt B et al: Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet 1992; 340: 1500-1502.
114. Farmer JA, Ballantyne CM, Frazier FOH et al: Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol 1991; 18: 926-930.
115. Webb AT, Reaveley DA, O'Donnel M, O'Connor B, Seed M, Brown EA: Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet 1993; 341: 268-270.
116. Jenner JL, Ordovas JM, Lamon-Fava S et al: Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. Circulation 1993; 87: 1135-1141.
117. Werba JP, Safa O, Gianfranceschi G, Michelagnoli S, Sirtori CR, Franceschini G: Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic italian population. Atherosclerosis 1993; 101: 203-211.
118. Steinmetz A, Kirklies A, Schlosser G et al: Partial caracterization of lipoproteins containing apo(a) in human atherosclerotic lesions. J Lipid Res 1993; 34: 789-798.
119. Glueck CJ, Glueck HI, Hamer T, Speirs J, Tracy T, Stroop D: Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity. Am J Med Sci 1994; 307: 317-324.
120. Hellsten G, Boman K, Hallmans G, Dahlén GH: Lipid and endurance physical activity. Atherosclerosis 1989; 75: 93-94.
121. Austin A, Janosky J, Warty W, Arslanian S: The relationship of physical fitness to lipids and lipoprotein(a) in adolescents with IDDM. Diabetes Care 1993; 16: 421-25.
122. Bown SA, Hutchinson R, Morrisett J et al: Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993; 13: 1139-1158.
123. Mendoza S, Velasquel E, Osana A, Hamer T, Glueck CJ: Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein(a). J Lab Clin Med 1994; 123: 837-841.
124. Haffner SM, Myccanen L, Gruber KK, Rainwater DL, Laaks M: Lack of association between sex hormones and Lp(a) concentrations in American and Finnish men. Arterioscler Thromb 1994; 14: 19-24.
125. Berg AL, Nillson-Ehle P: Direct effects of corticotropin on plasma lipoprotein metabolism in man-studies in vivo and in vitro. Metabolism 1994; 43: 90-97.
126. Edén S, Wiklund O, Oscarsson J, Rosén T, Bengtsson BA: Growth hormone treatment of growth hormone- deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993; 13: 296-301.
127. DeBruin TWA, Van Barlingen H, Van Linde- SibeniusTrip M, Van Vurstde Vries AR, Akveld NJ, Erkelens DW: Lipoprotein(a) and apoprotein B plasma concentrations in hypothyroid, euthyroid and hyperthyroid subjects. J Clin Endocrin Metab 1993; 76: 121-126.
128. Sees M, O'Connor B, Perombelon N, O'Donnel M, Realeley D, Knight BL: The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993; 101: 67-68.
129. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB: Levels of lipoprotein(a) decline with neomycin and niacin treatment. Atherosclerosis 1985; 57: 283-301.
130. Thiery I, Armstrong VW, Schleef J, Creutzfeldt C, Creutzfeldt W, Seidel D: Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reduttase inhibitor. Klin Wochenschr 1988; 66: 462-463.
131. Carlson LA, Hamsten A, Asplund A: Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271-276.
132. Brown SA, Morriset J, JR Patsch JR, Reeves R, Gotto AMJ, Patsch W: Influence of short dietary cholesterol and fat on human plasma Lp(a) and LDL levels. J Lipid Res 1991; 32: 1281-1289.
133. Huang CM, Elin RJ, Ruddel M, Schmitz J, Linnoila M: The effect of alcohol withdrawal on serum concentration of Lp(a), apolipoprotein A1 and B, and lipids. Alcohol Clin Exp Res 1992; 16: 895-898.
134. Naruszewicz M, Selinger E, Davignon J: Oxidative modification of Lp(a) and the effect of the beta carotene. Metabolism 1992; 41: 1215-1224.
135. Koizumi J, Koizumi I, Uno Y et al: Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 1993; 100: 65-74.
136. Spinier SA, Cziraky MJ: Lipoprotein(a): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother 1994; 28: 343-351.
137. Hajjar KA, Gavish D, Breslow JL, Nachman RL: Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherogenesis. Nature 1989; 339: 303-305.
138. Pepin JM, O'Neil JA, Hoff HF: Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res 1991; 32: 317-327.
139. Hoff HF, O'Neil J, Yashiro A: Partial characterization of lipoproteins containing apo(a) in human atherosclerotic lesions. J Lipid Res 1993; 34: 780-798.
140. Kreuzer J, Lloyd MB, Bok D, Fless GM, Scanu AM, Lusis AJ, Haberland ME: Lipoprotein(a) displays increased accumulation compared with LDL in the murine arterial wall. Chem Phys Lipids 1994; 67-68.
141. Hoff HP, O'Neil J, Smejkal GB, Yashiro A: Immunochemically detectable lipid-free apo(a) in plasma and in human atherosclerotic lesions. Chem Phys Lipids 1994; 67-68.
142. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM: Atherogenesis in transgenic mice expressing human lipoprotein(a). Nature 1992; 360: 631-632.
143. Steyrer E, Kostner GM: Interaction of lipoprotein Lp(a) with the B/E receptor: a study using isolated bovine adrenal cortex and human fibroblast receptors. J Lipid Res 1990; 31: 1247-1253.
144. Hofmann SL, Eaton DL, Brown MS, McConaty WJ, Goldstein JL, Hammer RE: Overexpression of human LDL receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Inv 1990; 85: 1542-1547.
145. Ghiselli G, Gaddi A: The relation of LDL receptor activity to lipoprotein(a) plasma concentration in patients without coronary artery disease. Chem Phys Lipids 1994; 67-68: 305-311.
146. Rader DJ, Mann A, Cain W et al: The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95: 1403-1408.
147. Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM: Interaction of recombinant apo(a) and Lp(a) with macrophages. J Clin Invest 1991; 87: 767-771.
148. Tabas I, Yveqing L, Broscia R, Wen Xu S, Swenson TL, Williams RJ: Lipoprotein lipase and sphyngomyelinase synergically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for LDL and Lp(a) retention and macrophage foam cells formation. J Biol Chem 1993; 268: 20419-20432.
149. Sugiyama N, Marcovina S, Gown AM, Seftel H, Joffe B, Chait A: Immunohistochemical distribution of lipoprotein epitopes in xanthomata from patients with familial hypercholesterolemia. Am J Pathol 1992; 141: 99-106.
150. Grainger DJ, Kirschenlor HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM: Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655-1658.
151. Tertov VV, Sobenin IA, Gabbasov ZA et al: Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation in human aortic intimal cells: the role of lipoprotein aggregation. Eur J Clin Chem Clin Biochem 1992; 30: 171-178.
152. Yashiro A, O'Neil J, Hoff H: Insoluble complex formation of lipoprotein(a) with LDL in presence of calcium ions. J Biol Chem 1993; 268: 4709-4715.
153. DeRijke YB, Jurgens G, Hessels EM, Hermann A, VanBerkel TJ: In vivo fate and scavenger receptor recognition of oxidized lp(a) isoforms in rats. J Lipid Res 1992; 33: 1315-1325.
154. Naruszewicz M, Giroux LM, Davignon J: Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a). Chem Phys Lipids 1994; 67-68: 167-174.
155. Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY: The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta 1993; 223: 73-82.
156. Wade DP, Clarke JG, Lindahl GE et al: Genetic influences on lipoprotein(a) concentration. Biochem Soc Trans 1993; 21-25: 499.
157. Dahlén GH, Slunga L, Lindblom B: Importance of Lp(a) lipoprotein and HLA genotypes in atherosclerosis and diabetes. Clin Genet 1994; 46: 46-51.
158. Seifert PS, Ruth I, Zioncheck TF: The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but not functionally (affects)(C3) activation or degradation. Atherosclerosis 1992; 93: 209-216.
159. Dahlén GH, Slunga L, Holmlund G, Lango A, Lindblom B: Lp(a) lipoprotein and HLA-DR genotype in early coronary artery disease. Eur J Immunogen 1993; 20: 95-102.
160. Linnanmaki E, Leinonen M, Mattila K, Nieminen S, Valtonen V, Saikku P: Chlamydia pneumoniae specific circulating immune complexes in patients with chronic coronary disease. Circulation 1993; 87: 1130-1134.
161. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT: Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167:841-849.
162. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EE: A potential basis for the thrombotic risks associated with Lp(a). Nature 1989; 339: 301-303.
163. Malle E, Ibovnik A, Steinmetz A, Kostner GM, Sattler W: Identification of glycoprotein IIb as the lipoprotein(a)-binding protein on platelets. Arterioscl Thromb 1994; 14: 345-352.
164. Smith EB, Thompson WD, Crosbie L, Stirk CM: Fibrinogen/fibrin in atherogenesis. Eur J Epidemiol 1992; 8: 83-87.
165. Smith EB: Fibrinogen and atherosclerosis. Wien Klin Wochenschr 1993; 105: 417-424.
166. Harpel PC, Chang VT, Borth W: Homocysteine and other sulphydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulphydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-10197.
167. Edelberg JM, Gonzales-Gronow M, Pizzo S: Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989; 28: 2370-2374.
168. Edelberg JM, Gonzales-Gronow M, Pizzo S: Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 1990; 57: 155-162.
169. Edelberg JM, Sane DC, Pizzo SV: Vascular regulation of plasminogen activator inhibitor-1 activity. Sem Thromb Hemost 1994; 20:319-323.
170. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL: Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266: 2459-2465.
171. Glueck CJ, Glueck HI, Speirs J, McCray C, Stroop D: Relationships between lipoprotein(a), lipids, apoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism 1993; 42: 236-246.
172. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
173. Carlos TM, Harlan JM: Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-2101.
174. Rollins BJ, Walz A, Baggiolini M: Recombinant human MCP1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 1991; 78: 1112-1116.
175. Collins T: Biology of disease: endothelial nuclear factor- kB and the initiation of the atherosclerotic lesion. Lab Invest 1993; 88: 499-508.
176. Nolan GP, Baltimore D: The inhibitory ankyrin and activator Rel proteins. Curr Opin Gen Develop 1992; 2: 211-220.
177. Liou H, Baltimore D: Regulation of the NF-xB/rel transcription factor and I-xB inhibitor system. Curr Opin Cell Biol 1993; 5: 477-487.
178. Bauerle PA, Henkel T: Function and activation of NF-xB in the immune system. Ann Rev Immunol 1994; 12: 141-179.
179. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H: Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990; 301: 1248-1251.
180. Sandcamp M, Funke H, Schulte H, Kole E, Assmann G: Lipoprotein(a) is an independent risk factor for myocardial infartion at young age. Clin Chem 1990; 36: 20-23.
181. Jauhiainen M, Koskinen F, Ehnholm U et al: Lipoprotein(a) and coronary heart disease risk: a nested case-control study of Helsinky Heart Study partecipants. Atherosclerosis 1991; 89: 59-67.
182. Labeur C, Debacque D, Debacher G et al: Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem 1992; 38: 2261-2266.
183. Abe A, Noma A, Lee YJ, Yamaguchi H: Studies on apolipoprotein(a) phenotypes. Part 2. Phenotype frequencies and Lp(a) concentrations in different phenotypes in patients with angiographically defined coronary artery disease. Atherosclerosis 1992; 96: 9-15.
184. Averna MR, Barbagallo CM, Ocello S et al: Lp(a) levels in patients undergoing aortocoronary by-pass surgery. Eur Heart J 1992; 1405-1409.
185. Kark JD, Sandholzer C, Friedlander Y, Utermann G: Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case control study in the Jerusalem population. Atherosclerosis 1993; 98: 139-151.
186. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of Lp(a) and the risk of myocardial infartion. JAMA 1993; 270: 2195-2199.
187. Simons L, Friedlander Y, Simons J, McCallum J: Lipoprotein(a) is not associated with coronary heart disease in elderly: cross-sectional data from the DUBBO study. Atherosclerosis 1993; 99: 87-95.
188. Kario K, Matsuo T, Imiya M et al: Close relation between lipoprotein(a) levels and atherothrombotic disease in Japanese subjects > 75 years of age. Am J Cardiol 1994; 73: 1187-1190.
189. Wang XL, Tarn C, McCredie RM, Wilcken DEL: Determinants of severity of coronary artery disease in Australian men and women. Circulation 1994; 89: 1974-1981.